254 related articles for article (PubMed ID: 23163762)
1. Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor.
Tamaichi H; Sato M; Porter AC; Shimizu T; Mizutani S; Takagi M
Cancer Sci; 2013 Feb; 104(2):178-84. PubMed ID: 23163762
[TBL] [Abstract][Full Text] [Related]
2. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
[TBL] [Abstract][Full Text] [Related]
3. Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses.
Fan JR; Peng AL; Chen HC; Lo SC; Huang TH; Li TK
DNA Repair (Amst); 2008 Mar; 7(3):452-63. PubMed ID: 18206427
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.
Zhao H; Traganos F; Darzynkiewicz Z
Cell Cycle; 2008 Oct; 7(19):3048-55. PubMed ID: 18802408
[TBL] [Abstract][Full Text] [Related]
5. Assessing acute myeloid leukemia susceptibility in rearrangement-driven patients by DNA breakage at topoisomerase II and CCCTC-binding factor/cohesin binding sites.
Atkin ND; Raimer HM; Wang Z; Zang C; Wang YH
Genes Chromosomes Cancer; 2021 Dec; 60(12):808-821. PubMed ID: 34405474
[TBL] [Abstract][Full Text] [Related]
6. Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM.
Bower JJ; Zhou Y; Zhou T; Simpson DA; Arlander SJ; Paules RS; Cordeiro-Stone M; Kaufmann WK
Cell Cycle; 2010 Apr; 9(8):1617-28. PubMed ID: 20372057
[TBL] [Abstract][Full Text] [Related]
7. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
[TBL] [Abstract][Full Text] [Related]
8. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
[TBL] [Abstract][Full Text] [Related]
9. Ataxia telangiectasia mutated (ATM) is dispensable for endonuclease I-SceI-induced homologous recombination in mouse embryonic stem cells.
Rass E; Chandramouly G; Zha S; Alt FW; Xie A
J Biol Chem; 2013 Mar; 288(10):7086-95. PubMed ID: 23355489
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
[TBL] [Abstract][Full Text] [Related]
11. ATM modulates the loading of recombination proteins onto a chromosomal translocation breakpoint hotspot.
Sun J; Oma Y; Harata M; Kono K; Shima H; Kinomura A; Ikura T; Suzuki H; Mizutani S; Kanaar R; Tashiro S
PLoS One; 2010 Oct; 5(10):e13554. PubMed ID: 21048951
[TBL] [Abstract][Full Text] [Related]
12. Functional switching of ATM: sensor of DNA damage in proliferating cells and mediator of Akt survival signal in post-mitotic human neuron-like cells.
Li Y; Xiong H; Yang DQ
Chin J Cancer; 2012 Aug; 31(8):364-72. PubMed ID: 22739265
[TBL] [Abstract][Full Text] [Related]
13. Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.
Kurose A; Tanaka T; Huang X; Halicka HD; Traganos F; Dai W; Darzynkiewicz Z
Cytometry A; 2005 Nov; 68(1):1-9. PubMed ID: 16184611
[TBL] [Abstract][Full Text] [Related]
14. Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement.
Oguchi K; Takagi M; Tsuchida R; Taya Y; Ito E; Isoyama K; Ishii E; Zannini L; Delia D; Mizutani S
Blood; 2003 May; 101(9):3622-7. PubMed ID: 12511424
[TBL] [Abstract][Full Text] [Related]
15. DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor.
Guo L; Liu X; Jiang Y; Nishikawa K; Plunkett W
Mol Pharmacol; 2011 Aug; 80(2):321-7. PubMed ID: 21546556
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
[TBL] [Abstract][Full Text] [Related]
17. Transcription-dependent activation of ataxia telangiectasia mutated prevents DNA-dependent protein kinase-mediated cell death in response to topoisomerase I poison.
Sakasai R; Teraoka H; Takagi M; Tibbetts RS
J Biol Chem; 2010 May; 285(20):15201-15208. PubMed ID: 20304914
[TBL] [Abstract][Full Text] [Related]
18. MEN1 is a melanoma tumor suppressor that preserves genomic integrity by stimulating transcription of genes that promote homologous recombination-directed DNA repair.
Fang M; Xia F; Mahalingam M; Virbasius CM; Wajapeyee N; Green MR
Mol Cell Biol; 2013 Jul; 33(13):2635-47. PubMed ID: 23648481
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms.
Siu WY; Lau A; Arooz T; Chow JP; Ho HT; Poon RY
Mol Cancer Ther; 2004 May; 3(5):621-32. PubMed ID: 15141020
[TBL] [Abstract][Full Text] [Related]
20. NPRL-Z-1, as a new topoisomerase II poison, induces cell apoptosis and ROS generation in human renal carcinoma cells.
Wu SY; Pan SL; Xiao ZY; Hsu JL; Chen MC; Lee KH; Teng CM
PLoS One; 2014; 9(11):e112220. PubMed ID: 25372714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
